Výsledky vyhledávání - "Kamchatnov Pavel"

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

[Asymptomatic cerebral infarctions: risk factors and cognitive impairment]

Autor: Rr, Zhetishev, Na, Mikhaĭlova, Ra, Ivashchenko, Kamchatnov Pavel

Publikováno v: Europe PubMed Central

Objectives. To study the risk factors of asymptomatic cerebral infarctions (AI) and their effect on cognitive functions. Material and methods. We examined 114 patients, aged from 53 to 88 years, including 58 patients with AI (group 1), 32 women and 2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::aa9dfbe263f89ce66ec518ef3efd2338
https://pubmed.ncbi.nlm.nih.gov/24781234

Zobrazit plný text záznamu

[Chronic disorders of brain blood circulation and possibilities of their pharmacological correction]

Autor: Kamchatnov Pavel, Gs, Sal Nikova, Na, Mikhaĭlova

Publikováno v: Europe PubMed Central

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::d05181964edf3eec2f6e1de8847fbd49
https://pubmed.ncbi.nlm.nih.gov/22983251

Zobrazit plný text záznamu

[Neuroprotective treatment with citicoline (ceraxon) in patients with ischemic stroke]

Autor: Martynov MIu, An, Boĭko, Kamchatnov Pavel, Aa, Kabanov, An, Iasamanova, Ia, Shchukin, Ti, Kolesnikova, Vi, Chubykin, Ap, Glukhareva, Ei, Gusev

Publikováno v: Europe PubMed Central

The dynamics of neurological symptoms assessed with the Scandinavian stroke scale, the Barthel index and the modified Rankin scale was studied in 89 patients with moderate ischemic stroke who received citicoline (ceraxone) intravenously and orally. T

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::a54e36a1578578c237a56f4fd7118a6d
https://pubmed.ncbi.nlm.nih.gov/22677765

Zobrazit plný text záznamu

[Efficacy of the combined treatment with artrosan and combilipen in patients with acute low-back pain]

Autor: Tt, Batysheva, Ov, Otcheskaia, Aa, Khozova, Pa, Ganzhula, Ka, Zaĭtsev, Kamchatnov Pavel, An, Boĭko

Publikováno v: Europe PubMed Central

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::ee238a48498e4d273aa2d00be1850e87
https://pubmed.ncbi.nlm.nih.gov/22027606

Zobrazit plný text záznamu

[The use of sirdalud MR in patients with multiple sclerosis]

Autor: Tt, Batysheva, Nf, Popova, Sv, Petrov, Kamchatnov Pavel, Ka, Zaĭtsev, An, Boĭko

Publikováno v: Europe PubMed Central

The study included 54 patients with multiple sclerosis, aged from 23 to 53 years (mean age 37.7 +/- 8.5 years). To reduce muscle tension, 34 patients of the main group received tizanidine with the modified release of active substance (sirdalud MR) in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::39fba8f42695a1ae4d73e7e188a5bc91
https://pubmed.ncbi.nlm.nih.gov/21322181

Zobrazit plný text záznamu

[Omaron in the complex treatment of patients with multiple sclerosis]

Autor: Nf, Popova, Kamchatnov Pavel, Ov, Riabukhina, Tt, Batysheva, Ka, Zaĭtsev, An, Boĭko

Publikováno v: Europe PubMed Central

We studied efficacy and tolerability of the combined drug omaron (25 mg of cinnarizine and 400 mg of piracetam in one tablet) in patients with multiple sclerosis. The dosage of the drug was 1 tablet 3 times a day during 12 weeks in 33 patients (mean

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::ce0c11d0a9021b49f41e13665a776074
https://pubmed.ncbi.nlm.nih.gov/21183917

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání